Abstract
Focused Ultrasound (FUS) is an emerging therapeutic strategy for neurological diseases, including Parkinson’s disease, Alzheimer’s disease, and brain tumors. Despite advancements in conventional treatments, challenges such as invasive procedures, limited drug delivery across the blood-brain barrier (BBB), and declining long-term efficacy necessitate novel approaches. FUS offers non-invasive neuroablation, BBB modulation, and enhanced drug delivery, positioning it as a promising alternative to traditional therapies. This review examines the clinical evidence on FUS’s role in tumor reduction, tremor management, and amyloid plaque reduction, highlighting its benefits, challenges, and future potential in neurological disease treatment.
Included in
Evaluating the Efficacy of Focused Ultrasound in Neurological Disorders and Malignancy
Focused Ultrasound (FUS) is an emerging therapeutic strategy for neurological diseases, including Parkinson’s disease, Alzheimer’s disease, and brain tumors. Despite advancements in conventional treatments, challenges such as invasive procedures, limited drug delivery across the blood-brain barrier (BBB), and declining long-term efficacy necessitate novel approaches. FUS offers non-invasive neuroablation, BBB modulation, and enhanced drug delivery, positioning it as a promising alternative to traditional therapies. This review examines the clinical evidence on FUS’s role in tumor reduction, tremor management, and amyloid plaque reduction, highlighting its benefits, challenges, and future potential in neurological disease treatment.